If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $169.63 which represents a decrease of $-0.72 or -0.42% from the prior close of $170.35. The stock opened at $170 and touched a ...

Asking dollar volume for luxury houses totals $124 million, with most properties selling “at a pretty robust pace.” ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $199.5 which represents a decrease of $-1.01 or -0.50% from the prior close of $200.51. The stock opened at $201.16 and touched a ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on schizophrenia asset emraclidine missed the primary endpoint. AbbVie ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...